CytoArm develops a non-viral bi-functional antibody (BsAb) therapy platform that enhances T-cell targeting of tumor cells, enabling adaptable treatments for over 50 types of cancers and autoimmune diseases. This technology addresses the need for effective and personalized cancer therapies by utilizing T cells to specifically target tumor markers.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often lack the precision to target tumor cells effectively, leading to off-target effects and limited efficacy across diverse cancer types. Traditional approaches may not fully harness the potential of T cells to selectively eliminate tumor cells, hindering the development of adaptable and personalized cancer treatments.
Solution
CytoArm is developing a bi-specific antibody (BsAb) Armed-T cell therapy platform designed to enhance T-cell mediated cancer treatment. The platform utilizes non-viral BsAbs to direct T cells to specific tumor markers, activating them for targeted tumor cell killing. This approach allows for the creation of adaptable cancer treatments applicable to a wide range of oncological conditions. By leveraging the specificity of BsAbs, CytoArm aims to improve the precision and efficacy of T-cell therapies, offering a potential solution for personalized cancer treatment. The BsAb Armed-T cells are designed to provide a more targeted and adaptable approach to cancer therapy, potentially overcoming the limitations of existing treatments.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer immunotherapies, as well as clinicians seeking more effective and adaptable treatment options for a broad range of cancers.
Features
- Non-viral bi-functional antibodies (BsAb) for arming T cells
- BsAbs designed to target specific tumor markers
- Adaptable platform applicable to over 50 different diseases
- Enhanced T-cell activation for targeted tumor cell killing